Summit Participation Policy

Updated for 2025

Since 2017, the Summit has convened influential leaders from across healthcare, genomics, and technology for a uniquely engaging, solution-oriented meeting on enabling cost-effective precision medicine at scale.

There is no other meeting like the Summit. Feedback from leaders who participate is consistent, from health plan CMOs and federal policymakers to clinical genetics experts and researchers to investors and entrepreneurs: The Summit brings together the necessary stakeholders to make meaningful change in the U.S. healthcare system.

Due to its unique format, the meeting has limited space and hits capacity each year. As demand for the meeting has continued to rise, the attendance policy was updated for 2023 and will continue in 2024.

Participation Policy:

  • Participation at the Summit is by invitation only, and invitations are non-transferrable. Invitations are issued on a rolling basis starting in mid-to-late June.

  • Organizations are generally limited to 1 representative. Organizers and speakers do not count against this limit. Exceptions are made on a case-by-case basis by Summit organizers. Additional participants beyond the 1st will need to register at the General Admission rate.

If you have any questions, please contact Nick Tazik at ntazik[at]concert.co.

PAST AUTHORS, SPEAKERS & ORGANIZERS

Titles and organizational affiliations are reflective of the time of the previous Summit and may have since changed.

  • FRANCIS COLLINS, MD, PhD

    Acting Science Advisor to the President of the United States
    White House

  • CARLOS BUSTAMANTE, PhD

    Founder & CEO
    Galatea Bio

  • TRISH BROWN, MS, CGC

    Genomics and Precision Medicine Program Director
    Aetna

  • GILLIAN HOOKER, PhD, ScM, CGC

    Chief Scientific Officer
    Concert Genetics

  • SUZANNE BELINSON, PhD, MPH

    VP, Commercial Markets
    Tempus

  • PRISCILLA ALFARO, MD

    VP, Payment Integrity
    BCBS North Carolina

  • VINCENT NELSON, MD

    SVP & Deputy CMO
    Centene

  • ROBERT NUSSBAUM, MD

    Chief Medical Officer
    Invitae

  • ANDY CORTS

    SVP, Research & Analytics
    SignalPath, a Verily company

  • BEN HO PARK, MD, PHD

    Professor & Director, Division of Hematology and Oncology
    Vanderbilt University Medical Center

  • ESTEBAN LÓPEZ

    Chief Medical Officer, Clinical Strategy Innovation
    HCSC (BCBS of IL, MT, NM, OK & TX)

  • SIMON BARNETT

    Genomics Analyst
    ARK Invest

  • DEE ANNA SMITH

    CEO
    Sarah Cannon

  • GEORGE CARDOZA

    Senior Vice President, Chief Financial Officer
    NeoGenomics

  • SEAN HOFHERR, PhD

    Chief Scientific Officer
    GeneDx, Inc.

  • JULIE M EGGINGTON, MS, PhD

    Co-founder & CEO
    Center for Genomic Interpretation

  • ERYNN GORDON, MS, LCGC

    VP, Clinical Operations
    Genome Medical

  • NIKOLETTA SIDIROPOULOS, MD

    Medical Director, Genomic Medicine, Department of Pathology and Laboratory Medicine
    University of Vermont Health Network

  • PHILLIP FEBBO, MD

    SVP & Chief Medical Officer
    Illumina

  • HOWARD LEVY, MD, PhD

    Associate Professor of Medicine
    Johns Hopkins Medicine

  • KATE DONIGAN, PHD

    Deputy Director, Personalized Medicine & Molecular Genetics (acting)
    FDA

  • JILL HAGENKORD, MD

    Chief Medical Officer
    Optum Genomics

  • JIM JIRJIS, MD

    Chief Health Information Officer
    HCA Healthcare

  • BENJAMIN SOLOMON, MD

    Clinical Director, National Human Genome Research Institute (NHGRI)
    NIH

  • HOLLI DILKS, MD

    Senior Director, Global Head of Field Medical
    Foundation Medicine

  • ROBERT C. GREEN, MD, MPH

    Director, Genomes2People
    Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School

  • JEFF EMCH

    VP, Diagnostics Strategy, Global Oncology Marketing
    GSK

  • NICOLE BOICE

    Founder & CEO
    Global Genes

  • DAVID MCCALLIE, MD

    SVP, Medical Informatics
    Cerner

  • EDWARD ABRAHAMS, PhD

    President
    Personalized Medicine Coalition

  • TAHA KASS-HOUT, MD

    Former 1st Chief Health Informatics Officer
    U.S. Food and Drug Administration (FDA)

  • GIL ALTEROVITZ, PhD

    Director, Biomedical Cybernetics Laboratory
    Harvard Medical School

  • KRISTINE BORDENAVE, MD

    Corporate Medical Director
    Humana

  • JOSHUA DENNY, MD

    Professor of Biomedical Informatics and Medicine
    Vanderbilt University

  • JAMES O’LEARY

    Chief Innovation Officer
    Genetic Alliance

  • HENRY GARLICH

    Director, Healthcare Value Solutions & Enhanced Clinical Programs
    Blue Shield of California

  • JIM ALMAS, MD

    VP & National Medical Director for Clinical Effectiveness
    LabCorp

  • MARA ASPINALL

    Managing Director and Co-Founder
    BlueStone Venture Partners

  • TRENT HAYWOOD, MD, JD

    SVP & Chief Medical Officer
    Blue Cross Blue Shield Association

  • STEPHANIE DEVANEY, PHD

    Deputy Director, All of Us
    NIH

  • EDMUND JACKSON, PHD

    Chief Data Officer
    HCA Healthcare

  • LISA ALDERSON

    Co-founder & CEO
    Genome Medical

  • DEBRA ESSER, MD

    Chief Medical Officer
    Blue Cross and Blue Shield of Nebraska

  • LAURIE MCGRAW

    SVP, Health Solutions
    American Medical Association

  • KATHRYN LANG, MD

    Global Medical Strategy Head of Data Science
    Pfizer

  • MATT MIGHT, PhD

    Director, Hugh Kaul Personalized Medicine Institute
    University of Alabama at Birmingham

  • VICTORIA PRATT, PhD

    President
    Association for Molecular Pathology

  • DAWN BARRY

    Co-Founder and President
    Luna DNA

  • ELI CASDIN

    Chief Investment Officer
    Casdin Capital

  • ELLEN MATLOFF, MS, CGC

    President & CEO
    My Gene Counsel

  • JULIE RAMAGE

    National Accounts Director, Diagnostics
    Pfizer

  • ALEX DE WINTER

    Managing Director
    GE Ventures

  • NICK NACLERIO, PhD

    Founding Partner
    Illumina Ventures

  • BRYCE OLSON

    Global Marketing Director, Health and Life Sciences
    Intel